CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)

Memorial Sloan Kettering Cancer Center, New York

New York Oncology Hematology, Albany

SUNY Upstate Medical University, Syracuse

University of Pittsburgh Medical Center Cancer Institute, Pittsburgh

University of Pennsylvania, Philadelphia

University of Maryland, Greenebaum Cancer Center, Baltimore

CAMC Health Education and Research Institute, Charleston

UNC Chapel Hill, Chapel Hill

Cancer Centers of the Carolinas, Greenville

Emory University, Atlanta

North Mississippi Hematology and Oncology Associates, Tupelo

Indiana University School of Medicine, Indianapolis

Franciscan St. Francis Health, Indianapolis

Ann Arbor Hematoloty-Oncology, Ann Arbor

Karmanos Cancer Institute, Detroit

June E. Nylen Cancer Center, Sioux City

St. Vincent Regional Cancer Center CCOP, Green Bay

Decatur Memorial Hospital, Decatur

The University of Kansas Cancer Center, Fairway

Cancer Center of Kansas, Wichita

University of Nebraska Medical Center, Omaha

Our Lady of the Lake Physician Group, Baton Rouge

Texas Oncology, Flower Mound, Flower Mound

Texas Oncology, Dallas, Dallas

Texas Oncology, Fort Worth, Fort Worth

Texas Oncology, P.A., Houston

Cancer Center Network of South Texas, San Antonio

Texas Oncology P.A., Austin

Texas Oncology, Amarillo, Amarillo

Texas Oncology, El Paso, El Paso

Rocky Mountain Cancer Centers, Denver

Utah Cancer Specialists, Salt Lake City

Comprehensive Cancer Centers of Nevada, Las Vegas

David Geffen School of Medicine UCLA, Los Angeles

Cedars Sinai Medical Center, Los Angeles

University of California San Diego, La Jolla

Kaiser Permanente, Honolulu

MD Anderson Cooper Cancer Institute, Voorhees Township

National Cancer Center, Goyang-si Gyeonggi-do

Seoul National University Hospital, Seoul

Severence Hospital, Seoul

Samsung Medical Center, Seoul

Asan Medical Center, Seoul